Technology

CAPTEC technology is to be introduced for several types of cancer. Besides this, the technology is to be implemented in different forms of viremia, (SARS-CoV-2, HIV type 1-2) where the technology used for viral particle removal is based on the same unique antigen-antibody microfluid filtration method used for cancer. The CAPTEC technology is the first extracorporeal hemoperfusion technology for the removal of Circulating Tumor Cell (CTC) and viral particles from the bloodstream. In the design process CAPTEC placed emphasis on the ease of clinical application. Standard fittings were designed specifically for easy adaptation to already existing, widely used instruments in hospitals, as in hemodialysis and hemoperfusion.

 

Patents

CAPTEC Medical Ltd. has a long-term contract with the leading Hungarian IP firm, to develop and manage its patent portfolio. Our IP experts are continuously monitoring patent applications. The following applications have been filed:

  • US201662367650P, A. Guttman, G. Jarvas, M. Szigeti, Design and in-situ preparation of a therapeutic CTC and/or pathogen flow-capture device, US Provisional application. Transferred to PCT/HU/2017/050032. EPA and USPTO issued ready to granting in 2023 Q1.
  • PCT/HU/2017/050032, A. Guttman, G. Jarvas, M. Szigeti, Flow capture device and method for removing cells from blood, PCT application currently holds pending status. EPA and USPTO issued ready to granting in 2023 Q1.
  • #P2200216, G. Jarvas, P. Stolk, J. Tovari, L. Takacs, A. Guttman, A high performance immuno-affinity based extracorporeal capture system, PCT application currently holds pending status.